Bortezomib 2MG INJECTION

Bortezomib 2mg injection contains bortezomib, a prescription anticancer medicine used in the treatment of multiple myeloma and mantle cell lymphoma. It belongs to the class of proteasome inhibitors and plays an important role in controlling the growth and spread of cancer cells.

Bortezomib works by blocking the proteasome system inside cancer cells, which leads to the accumulation of damaged proteins and ultimately causes cancer cell death. Bortezomib 2 mg injection is administered intravenously or subcutaneously under strict medical supervision in hospital or oncology clinic settings.

Bortezomib 2mg Injection is offered through an established pharmaceutical distribution network. The product is handled in compliance with proper storage and quality standards to ensure safety, consistency, and dependable availability.

Product Features

• Targeted anticancer injection
• Contains Bortezomib 2 mg
• Proteasome inhibitor chemotherapy
• Used in multiple myeloma and mantle cell lymphoma
• Administered intravenously or subcutaneously
• Sterile lyophilized injectable formulation
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Inhibits proteasome activity to stop cancer cell growth
• Promotes the accumulation of damaged proteins in cancer cells
• Induces cancer cell death (apoptosis)
• Helps control disease progression in multiple myeloma and mantle cell lymphoma